Early Brain Changes of Non-Amyloid Pathways Charles DeCarli, MD Victor and Genevieve Orsi Chair in Alzheimer's Research Director University of California.

Slides:



Advertisements
Similar presentations
Journal Club Article 1 Influence of Education on Subcortical Hyperintensities and Global Cognitive Status in Vascular Dementia.
Advertisements

APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.
Stroke Research in East Kent Prevention and Treatment Present and Future Dr Tom Webb Consultant Neurologist and Stroke Physician EKHUFT June 2014.
Extent and Distribution of White Matter Hyperintensities in Normal Aging, Mild Cognitive Impairment and Alzheimer’s Disease Mitsuhiro Yoshita, Evan Fletcher,
Significance of White Matter Hyperintensities in MCI Charles DeCarli University of California at Davis Alzheimer’s Disease Center Imaging of Dementia and.
Hypertension and Stroke
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
MILD COGNITIVE IMPAIRMENT IN PATIENTS WITH CAROTID DISEASE Irena Martinic Popovic 1, M.D, Arijana Lovrencic-Huzjan 1, M.D, Ph. D, Ana-Maria Simundic 2,
GAL-INT-6 The safety and efficacy of galantamine in patients with Vascular dementia or AD with cerebrovascular disease Sean Lilienfeld MD, FCP, MMed Janssen.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Of Let’s have a brief discussion on…. From T. MADHAVAN, M.Sc., M.L.I.S., M.Ed., M.Phil., P.G.D.C.A., Lecturer in Zoology.. ~ ~ STROKE~ ~ STROKE. ~ ~ BRAIN.
Dr. Omranifard MD 12 may 2015 Depression is one of the most prevalent psychiatric disorders in late life with devastating health consequences. It could.
Epidemiology of Stroke Dexter L. Morris, PhD, MD Department of Emergency Medicine University of North Carolina School of Medicine Chapel Hill, NC.
Subtype of VaD: SIVD Subcortical Ischemic Vascular Disease Helena Chui, M.D. University of Southern California Rancho Los Amigos National Rehabilitation.
Life Line Screening: Age and gender specific prevalence of AAA, PAD, carotid stenosis and AF and their associations with smoking Sarah Lewington CTSU,
Screening for Stroke and Cognitive Impairment Chapter 2: Background.
Health Status of Australian Adults. The health status of Australians is recognised as good and is continually improving. The life expectancy for males.
CHAPTER TWO CHAPTER TWO Neuroscience as a Basis for Adult Development and Aging.
The Healthy Body, Healthy Brain Campaign Alaska Commission on Aging Alaska Division of Public Health Alaska Mental Health Trust Legislative Health Caucus.
Dementia Reed Radford. What is dementia?  Dementia is a serious loss of global cognitive ability, beyond what might be expected from normal aging. 
Latent Variable Modeling of Neuropathology Data: Implications for Collaborative Science Dan Mungas University of California, Davis Friday Harbor Psychometrics,
Menopause and the Brain: Lifting the Fog Majid Fotuhi, MD PhD.
Slide 1 of 25 From VG Valcour, MD, at Washington, DC: June 18, 2013, IAS-USA. IAS–USA Victor G. Valcour, MD Professor of Geriatric Medicine University.
Processing Speed Training: Does it work? Lesley A. Ross, PhD Center for Healthy Aging Department of Human Development and Family Studies College of Health.
Grow Your Brain at Any Age Majid Fotuhi, MD PhD Howard County Office on Aging Columbia, MD March 28, 2014.
ASNR 2015 Poster# EP-19 Effect of Chemotherapy on Brain Structure and Cognition in Older Women with Breast Cancer: a Brain MRI Study 1 Bihong T. Chen MD.
Jack Twersky, MD Medical Director CLC Durham.  Memory impairment and at least one of the following  Aphasia  Apraxia  Agnosia  Executive function.
Six Steps to a Better Brain Majid Fotuhi, MD PhD March 6, 2014.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Utilization Of Lipid-lowering Therapy In Hypertensive Patients In The United States Simon S.K. Tang, MPH* Sean Candrilli, MS** Lizheng Shi, PhD* *Department.
How To Grow Your Hippocampus in Three Months Majid Fotuhi, MD PhD Founder and Chief Medical Officer NeurExpand Brain Center Nothing to disclose.
Howard County 4 th Annual Health & Wellness Expo May 1, 2015 Boost Your Brain: Regenerate Cells Critical to Memory & Learning Majid Fotuhi, MD PhD.
Survey of alternative uses of ACTIVE data, review of completed work and lessons learned Friday Harbor Advanced Psychometrics Workshop June 9-13, 2014 Presenter:
MRI as a Potential Surrogate Marker in the ADCS MCI Trial
Friday Harbor Psychometrics 2012 Scientific Summary UC Davis / SENAS (Spanish and English Neuropsychological Assessment Scales)
Brain Atrophy in Type 2 Diabetes Regional distribution and influence on cognition Featured Article: Chris Moran, M.B., B.C.H., Thanh G. Phan, P.H.D., Jian.
Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.
Is It Alzheimer’s? The Latest Update on Optimal Evaluation and Treatment of Patients with Memory Loss Majid Fotuhi, MD PhD March 5, 2014.
Microstructural White Matter Abnormalities and Cognitive Functioning in Type 2 Diabetes A Diffusion Tensor Imaging Study Featured Article: Yael D. Reijmer,
Ethnicity and Cardiovascular Disease Africans Americans.
High resolution MRI at 21.1 T of the hippocampus and temporal lobe white matter in the differential classification of Alzheimer’s Disease & Diffuse Lewy.
The Alzheimer’s Disease Challenge: Take Your Knowledge Further ALZHEIMER’S DISEASE AND ITS MANAGEMENT: AN OVERVIEW.
The role of neuroinflammation in the determination of regional and neuronal vulnerability in Alzheimer’s disease Holly M. Brothers & Gary L. Wenk Department.
BY: GRACE STOUT. What is Alzheimer’s and what does it do to the human body?  Alzheimer’s Disease is a progressive, neurodegenerative disorder that is.
UC Davis Alzheimer’s Disease Center The Residual Approach to Measuring Cognitive Reserve in Aging and Dementia Bruce Reed & Dan Mungas University of California,
Latent Variable Modeling of Cognitive Reserve Richard N. Jones, Sc.D. Friday Harbor Advanced Psychometrics Workshop 2009.
Comparison of Risk Factors for Early-Onset versus Late-Onset Alzheimer Disease OBJECTIVE To compare early-onset (before 65) Alzheimer disease (AD) patients.
DIABETES AS A RISK FACTOR FOR COGNITIVE DECLINE IN OLDER PATIENTS F. Limongi, A. Marseglia, S. Maggi, M. Noale, G. Romanato, P. Siviero, G. Crepaldi CNR,
The Link Between Persistent Atrial Fibrillation and Dementia
Metabolic Syndrome and Progression of Mild Cognitive Impairment
Update on Cognitive Health and Dementia
Poststroke dementia Vikas Dhikav,
Associations Between Regional Brain Volumes and the NIH-Toolbox Cognition Battery Fluid and Crystallized Composite Scores in Cognitively Healthy Older.
Associations of renal impairment (adjusted odds ratio and 95% CI) and the presence of individual small vessel disease markers stratified by age. Associations.
Imaging AD Progression Amyloid Imaging Agents.
Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation  Lena Rivard, MD, MSc, Paul Khairy, MD,
Heart Disease and Stroke Statistics — 2004 Update
Early Cognitive Decline and the Aging Brain - Overview
The Ageing Brain Fergus Doubal October 2007.
Adam P. Spira, Ph.D. Associate Professor, Department of Mental Health
Figure 1 The trajectory of cognitive ageing
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
Studies of Cognitive Reserve in WHICAP
Cognitive Reserve Concepts
The Cardiovascular Health Study:
Rubin Becker MD FRCP© Associate Professor McGill University Medical Consultant Manulife and OptimumRe.
UC Davis Data Summary Psychometrics 2018.
University of California, Santa Cruz August 24-29, 2008
in Younger and Older African Americans and Whites
Association between cognitive impairment and cerebrovascular disease
Presentation transcript:

Early Brain Changes of Non-Amyloid Pathways Charles DeCarli, MD Victor and Genevieve Orsi Chair in Alzheimer's Research Director University of California at Davis, Alzheimer’s Disease Center

Acknowledgements  Funded in part by Grant R13 AG from the National Institute on Aging  The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Outline  Brain Aging: cognition and structural imaging  Potential Causes of heterogeneity Amyloidosis (brief) Amyloidosis (brief) Vascular risk factors Vascular risk factors  Time course of vascular risk on brain  Inflammation and brain aging

Cross-sectional and Longitudinal Memory Performance Wilson et al, Arch Neuro, 1999 Wilson et al,Psychology and Aging, 2002

Clinical Consequences Mungas, et al. Psychology and Aging, 2010

MRI Measures of Atrophy

Variability in Brain Aging

Summary  Brain aging is heterogeneous Cognition Cognition Brain structure Brain structure

Outline  Brain Aging: cognition and structural imaging  Potential Causes of heterogeneity Amyloidosis (brief) Amyloidosis (brief) Vascular risk factors Vascular risk factors  Time course of vascular risk on brain  Inflammation and brain aging

Percent PiB+ with Age Morris et al, Annals of Neuro, 2010

Time Dependent Differences Jack, et al. JAMA Neurology, 2015

Framingham Heart Study, unpublished data

Prevalence of Vascular Risk Factors among the Framingham Offspring MeasureResult Age Percent Obese33 Percent hypertensive52 Percent treated hypertensive40 Percent Diabetic13 Percent current smoker14 Percent CAD17 Percent MI6 Percent stroke/TIA4 Percent atrial fibrillation5 DeCarli, et al. Neurobiology of Aging, 2005

Seshadri, S. et al. Stroke 2006;37: Future Risk of Stroke or Dementia at Age 65 Women Men

Spectrum of CVD MRI Infarction Stroke White Matter Hyperintensities Brain Atrophy

MRI Examples of WMH and SBI Normal WMH Extensive WMH Silent MRI Infarct Debette et al, Stroke, 2010

Age-Specific Prevalence of SBI DeCarli, et al. Neurobiology of Aging, 2005

Aging White Matter Disease Vascular Risk DeCarli, et al. Neurobiology of Aging, 2005

 Quantification of age- related differences in WMH  Define Large WMH as 1 sd above age-related mean WMH

Vascular Risk and WMH

WomenMenSBP HTN Rx 15%18% Diabetes4%7% Smoker16%17% History of CVD 4%8% Atrial fibrillation 0.2%0.7% ECG- LVH 4%14% FSRP score

Risk Factors, Age and Brain Volume

Cognitive Consequences

Middle Life Vascular Risk Factors and Dementia Risk Whitmer, et al, Neurology, 2005

Increasing odds of Dementia with number of Risk Factors* Whitmer, et al, Neurology, 2005*~74% Caucasian

Dementia Risk with MRI Vascular Measures Debette et al, Stroke, 2010

0 VR 1 VR 2 VR 3 VR  Significant change in FA  Significant negative Jacobians  Both Impact of Vascular Risk (VR) on White Matter Integrity and Gray Matter Atrophy Maillard et al, Neurobiology of Aging, 2015

Significant FA loss /year Significant Atrophy /year ** * Number of VR ** *

*** * * Number of Vascular Risk Factors Annual change in hippocampus volume

Summary II  Vascular risk factors are common  Vascular risk factors affect the brain Silent brain infarctions Silent brain infarctions WMH WMH Cerebral Atrophy Cerebral Atrophy  Vascular risk factors affect cognition and brain structure in a dose dependent fashion

Outline  Brain Aging: cognition and structural imaging  Potential Causes of heterogeneity Amyloidosis (brief) Amyloidosis (brief) Vascular risk factors Vascular risk factors  Time course of vascular risk on brain  Inflammation and brain aging

Impact of Vascular Disease may begin early Maillard, et al, Lancet Neurology, 2013

Neurology, 2015

Diabetes and Brain Aging

Cognitive Consequences

Hypothetical Model of Vascular Disease and Brain Atrophy

Hypothetical Consequences Cognition VRF VBI SNAP?

Summary III  Advancing age is associated with co- morbid diseases Alzheimer’s pathology Alzheimer’s pathology Cerebrovascular pathology Cerebrovascular pathology  Vascular injury may begin early in life The number of vascular risk factors appears additive to later life dementia risk The number of vascular risk factors appears additive to later life dementia risk  Vascular risk may contribute to neurodegeneration in SNAP

Outline  Brain Aging: cognition and structural imaging  Potential Causes of heterogeneity Amyloidosis (brief) Amyloidosis (brief) Vascular risk factors Vascular risk factors  Time course of vascular risk on brain  Inflammation and brain aging

Atheroscler, Thromb, Vasc, Bio, 2011

Inflammation in Younger Individuals Interaction p-value indicates significant differences by younger versus older

Inflammation and Cognition

GDF-15 in Brain Immunostaining of human cortex from individual who had mixed dementia (AD+vascular dementia). Blue=cell nuclei stained with DAPI. Green=microglia stained with IBA-1. Red =immunostaining for GDF15. Colocalization of GDF15 is noted in microglia (arrows). Bar = 20um.

Model of Inflammation and Brain Pathology in Aging

Summary IV  Aging and atherosclerosis lead to increasing inflammation  Inflammation can lead to brain injury and cognitive decline independent of vascular risk factors  Inflammation may lead to microglial activation with release of harmful cytokines

Conclusions  Brain aging is heterogeneous  Vascular risk factors cause subtle brain injury and cognitive impairment in a dose dependent manner  Cerebral atrophy is a common consequence of vascular risk  Inflammation secondary to systemic atherosclerosis may mediate some of the atrophic process

UC Davis Alzheimer’s Disease Center Supported by NIH: P30 AG10129, P01 AG12435, R01 AG010220, R01 AG021028, R01 AG031252, R01 AG , DHS , K01 AG Charles DeCarli Charles DeCarli Dan Mungas Dan Mungas John Olichney John Olichney Sarah Farias Sarah Farias Berneet Kaur Berneet Kaur Bruce Reed Bruce Reed Ladson Hinton Ladson Hinton Laurel Beckett Laurel Beckett Danielle Harvey Danielle Harvey Cam Carter Cam Carter Owen Carmichael Owen Carmichael Lee-Way Jin Lee-Way Jin Joshua Miller Joshua Miller

IDeA Lab  Owen Carmichael  Evan Fletcher  Baljeet Singh  Noel Smith  Alexandra Roach  Samuel Lockhart  Jing He  Pauline Maillard Supported by NIH and the Dana Foundation